MW: 48,542 Da. Purity as determined by densitometric image analysis is >95%. Introduction: Kallistatin (SERPINA4) inhibits human amidolytic and kininogenase activities of tissue kallikrein. This inhibition is attained by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and production of a small C-terminal fragment of the inhibitor as a result of cleavage at the reactive site by tissue kallikrein.Description: SERPINA4 Human Recombinant produced
Size
0.002 mg, 0.01 mg, 1 mg
Concentration
n/a
Applications
n/a
Other Names
[SERPINA4 Human; Kallistatin Human Recombinant; Serpin Peptidase Inhibitor; Clade A (Alpha-1 Antiproteinase; Antitrypsin) Member 4; PI4; KST; Serine (Or Cysteine) Proteinase Inhibitor; Clade A (Alpha-1 Antiproteinase; Antitrypsin); Member 4; Peptidase Inhibitor 4; Kallikrein Inhibitor; Serpin A4; PI-4; Protease Inhibitor 4 (Kallistatin); Kallistatin; KLST; KAL; SERPINA4]